Our tentative explanation for the effects that ODC generated on the selected AML cell lines in vitro implies the exciting hypothesis that combining PARP inhibitors and anthracyclines can capitalize on two defective apparatuses in AML: DNA repair, autophagy or possible cell differentiation by olaparib. The gene discussed is PARP1; the disease is acute myeloid leukemia.